Could Cell-Derived vesicles heal skin wounds in epidermolysis bullosa?

NCT ID NCT07230223

Recruiting now Disease control Sponsor: Isfahan University of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1/2 trial tests a topical treatment called Ev.FV, made from cell-derived particles, to help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a genetic skin condition causing painful blisters. The study will enroll 20 participants with active wounds and measure wound closure and disease activity over several weeks. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ev.FV (extracellular vesicles)
What this could lead to: If successful, this could point toward a new topical treatment to help heal wounds in people with epidermolysis bullosa.
What could go wrong: This is a very early phase 1/2 trial with only 20 participants, so results may not apply to all patients. The treatment may not improve wound healing or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dystrophic epidermolysis bullosa, dog epidermolysis bullosa dystrophica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSTROPHIC EPIDERMOLYSIS BULLOSA WOUND HEAL

Contacts and locations

Locations

Alzahra Hospital
RECRUITING

Isfahan, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.